Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States

Key Points

• This research aims to examine the impact of semaglutide on healthcare costs in patients with obesity and multimorbidity.
• Analyzed medical costs for patients treated with semaglutide versus non-users
• Compared all-cause and obesity-related costs
• Evaluated hospitalization rates and associated costs
• Semaglutide users experienced a yearly cost reduction of $3,870
• Users had $3,482 lower costs related to obesity
• Hospitalization rates and costs were significantly lower for those treated with semaglutide